Hyperbaric oxygen therapy across acute and post-acute phases after out-of-hospital cardiac arrest: a multi-cohort randomized controlled pilot study (HOT-RESUS 1)

Abstract Hyperbaric oxygen therapy (HBOT) after out-of-hospital cardiac arrest (OHCA) remains untested in humans despite promising preclinical evidence. We thus evaluated feasibility, tolerability, observed treatment-related adverse events, and early biological signals of HBOT across three distinct clinical cohorts and exposure subgroups. This prospective, single-centre, randomized, controlled, open-label pilot study enrolled (i) Intensive Care Unit (ICU) patients with sustained return of spontaneous circulation (ROSC) within the preceding 24 h, (ii) long-term OHCA survivors, and (iii) healthy volunteers. Within each cohort, participants were randomized to no HBOT, one HBOT session, or five HBOT sessions. Assessments included serial laboratory biomarkers, vascular function, neurocognitive testing, and patient-reported outcomes. Analyses were primarily descriptive, with additional between-group comparisons considered exploratory. The prespecified recruitment target was achieved (45/45 participants), all assigned HBOT sessions were completed (90/90; 100%), and all scheduled blood samples were obtained. No HBOT-related adverse events occurred. In ICU patients, serial biomarkers demonstrated pronounced temporal changes during the acute post-cardiac-arrest phase across inflammatory, oxidative stress, endothelial dysfunction, neuronal injury, and myocardial injury domains, whereas direct comparison of trajectories between HBOT groups were generally inconclusive. In long-term OHCA survivors and healthy volunteers, exploratory analyses suggested reductions in arterial stiffness and, particularly among survivors, favourable changes in neurocognitive and patient-reported outcomes, with several favourable numerical patterns observed in HBOT-exposed groups. Given the small subgroup sizes, extensive multiplicity, and generally inconclusive direct between-group comparisons, these findings remain exploratory. HOT-RESUS 1 demonstrated that the prespecified recruitment and HBOT procedures could be completed as planned, including treatment of selected acute post-ROSC ICU patients in a specialised hyperbaric centre, with no HBOT-related adverse events observed. Exploratory analyses showed dynamics of inflammatory and oxidative stress markers, arterial stiffness, and neurocognitive and patient-reported outcomes, with several favourable numerical patterns observed in HBOT-exposed groups. Although the small pilot sample, extensive multiplicity, and largely inconclusive direct between-group comparisons preclude attribution of these changes to HBOT or conclusions regarding biological or clinical efficacy, the findings identify possible biological and functional outcomes for further investigation in adequately powered randomized trials.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-15
DOI
https://doi.org/10.1038/s41598-026-76474-0
Primary Topic
Cardiac Arrest and Resuscitation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hyperbaric oxygen therapy across acute and post-acute phases after out-of-hospital cardiac arrest: a multi-cohort randomized controlled pilot study (HOT-RESUS 1)

Philip Verdonck, Oliver Schlager, Rudi De Paep, Gaëlle Vermeersch et al.
Scientific Reports
Cardiac Arrest and Resuscitation
article

Hyperbaric oxygen therapy across acute and post-acute phases after out-of-hospital cardiac arrest: a multi-cohort randomized controlled pilot study (HOT-RESUS 1)

Philip Verdonck, Oliver Schlager, Rudi De Paep, Gaëlle Vermeersch, Johan B. Saenen, Patrick Sulzgruber, Sebastian Schnaubelt, Philippe G. Jorens, Annemiek Snoeckx, Koenraad G. Monsieurs, Cathérine De Maeyer, Carlo Strouven
article en

Abstract

Abstract Hyperbaric oxygen therapy (HBOT) after out-of-hospital cardiac arrest (OHCA) remains untested in humans despite promising preclinical evidence. We thus evaluated feasibility, tolerability, observed treatment-related adverse events, and early biological signals of HBOT across three distinct clinical cohorts and exposure subgroups. This prospective, single-centre, randomized, controlled, open-label pilot study enrolled (i) Intensive Care Unit (ICU) patients with sustained return of spontaneous circulation (ROSC) within the preceding 24 h, (ii) long-term OHCA survivors, and (iii) healthy volunteers. Within each cohort, participants were randomized to no HBOT, one HBOT session, or five HBOT sessions. Assessments included serial laboratory biomarkers, vascular function, neurocognitive testing, and patient-reported outcomes. Analyses were primarily descriptive, with additional between-group comparisons considered exploratory. The prespecified recruitment target was achieved (45/45 participants), all assigned HBOT sessions were completed (90/90; 100%), and all scheduled blood samples were obtained. No HBOT-related adverse events occurred. In ICU patients, serial biomarkers demonstrated pronounced temporal changes during the acute post-cardiac-arrest phase across inflammatory, oxidative stress, endothelial dysfunction, neuronal injury, and myocardial injury domains, whereas direct comparison of trajectories between HBOT groups were generally inconclusive. In long-term OHCA survivors and healthy volunteers, exploratory analyses suggested reductions in arterial stiffness and, particularly among survivors, favourable changes in neurocognitive and patient-reported outcomes, with several favourable numerical patterns observed in HBOT-exposed groups. Given the small subgroup sizes, extensive multiplicity, and generally inconclusive direct between-group comparisons, these findings remain exploratory. HOT-RESUS 1 demonstrated that the prespecified recruitment and HBOT procedures could be completed as planned, including treatment of selected acute post-ROSC ICU patients in a specialised hyperbaric centre, with no HBOT-related adverse events observed. Exploratory analyses showed dynamics of inflammatory and oxidative stress markers, arterial stiffness, and neurocognitive and patient-reported outcomes, with several favourable numerical patterns observed in HBOT-exposed groups. Although the small pilot sample, extensive multiplicity, and largely inconclusive direct between-group comparisons preclude attribution of these changes to HBOT or conclusions regarding biological or clinical efficacy, the findings identify possible biological and functional outcomes for further investigation in adequately powered randomized trials.

Scientific Reports
Danube Private University (AT), University of Antwerp (BE), Antwerp University Hospital (BE), Göttlicher Heiland Krankenhaus Wien (AT), Ziekenhuis aan de Stroom (BE), Medical University of Vienna (AT)
Austrian Science Fund, Laerdal Foundation for Acute Medicine
Good health and well-being
Cardiac Arrest and Resuscitation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon